{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:14:33Z","timestamp":1773483273863,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","award":["IRP-NIMH-NIH; ZIAMH002927"],"award-info":[{"award-number":["IRP-NIMH-NIH; ZIAMH002927"]}],"id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-025-02143-7","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:28:52Z","timestamp":1765189732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial"],"prefix":"10.1038","volume":"8","author":[{"given":"Joseph","family":"Geraci","sequence":"first","affiliation":[]},{"given":"Bessi","family":"Qorri","sequence":"additional","affiliation":[]},{"given":"Mike","family":"Tsay","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Cumbaa","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Leonczyk","sequence":"additional","affiliation":[]},{"given":"Larry","family":"Alphs","sequence":"additional","affiliation":[]},{"given":"Elizabeth D.","family":"Ballard","sequence":"additional","affiliation":[]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2143_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel, D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun. 11, 156 (2018).","journal-title":"Contemp. Clin. Trials Commun."},{"key":"2143_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.7326\/M18-3667","volume":"172","author":"DM Kent","year":"2019","unstructured":"Kent, D. M. et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann. Intern Med. 172, 35 (2019).","journal-title":"Ann. Intern Med."},{"key":"2143_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell, P. M. Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365, 176\u2013186 (2005).","journal-title":"Lancet"},{"key":"2143_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/cts.12980","volume":"14","author":"S Yamaguchi","year":"2021","unstructured":"Yamaguchi, S., Kaneko, M. & Narukawa, M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin. Transl. Sci. 14, 1113 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"2143_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm.4246","volume":"23","author":"AT Drysdale","year":"2017","unstructured":"Drysdale, A. T. et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat. Med. 23, 28\u201338 (2017).","journal-title":"Nat. Med."},{"key":"2143_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S2215-0366(15)00471-X","volume":"3","author":"AM Chekroud","year":"2016","unstructured":"Chekroud, A. M. et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 3, 243\u2013250 (2016).","journal-title":"Lancet Psychiatry"},{"key":"2143_CR7","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J. & Drazen, J. M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357, 2189\u20132194 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2143_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/sim.7064","volume":"36","author":"I Lipkovich","year":"2017","unstructured":"Lipkovich, I., Dmitrienko, A. & D\u2019Agostino, R. B. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials. Stat. Med. 36, 136\u2013196 (2017).","journal-title":"Stat. Med."},{"key":"2143_CR9","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/sim.4322","volume":"30","author":"JC Foster","year":"2011","unstructured":"Foster, J. C., Taylor, J. M. G. & Ruberg, S. J. Subgroup identification from randomized clinical trial data. Stat. Med. 30, 2867\u20132880 (2011).","journal-title":"Stat. Med."},{"key":"2143_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrd1470","volume":"3","author":"I Kola","year":"2004","unstructured":"Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711\u2013716 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2143_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrd2251","volume":"6","author":"MR Trusheim","year":"2007","unstructured":"Trusheim, M. R., Berndt, E. R. & Douglas, F. L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6, 287\u2013293 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2143_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04976-x","volume":"22","author":"EH Weissler","year":"2021","unstructured":"Weissler, E. H. et al. The role of machine learning in clinical research: transforming the future of evidence generation. Trials 22, 1\u201315 (2021).","journal-title":"Trials"},{"key":"2143_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","volume":"40","author":"S Harrer","year":"2019","unstructured":"Harrer, S., Shah, P., Antony, B. & Hu, J. Artificial intelligence for clinical trial design. Trends Pharm. Sci. 40, 577\u2013591 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"2143_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12248-021-00644-3","volume":"24","author":"S Kolluri","year":"2022","unstructured":"Kolluri, S., Lin, J., Liu, R., Zhang, Y. & Zhang, W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 24, 19 (2022).","journal-title":"AAPS J."},{"key":"2143_CR15","doi-asserted-by":"crossref","unstructured":"Ribeiro, M. T., Singh, S. & Guestrin, C. \u2018Why should I trust you?\u2019 Explaining the predictions of any classifier. In Proc. ACM SIGKDD International Conference on Knowledge Discovery and Data Mining 13\u201317 August 2016, 1135\u20131144 (ACM, 2016).","DOI":"10.1145\/2939672.2939778"},{"key":"2143_CR16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/s23020634","volume":"23","author":"A Chaddad","year":"2023","unstructured":"Chaddad, A., Peng, J., Xu, J. & Bouridane, A. Survey of explainable AI techniques in healthcare. Sensors 23, 634\u2013634 (2023).","journal-title":"Sensors"},{"key":"2143_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","volume":"1","author":"C Rudin","year":"2019","unstructured":"Rudin, C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat. Mach. Intell. 1, 206\u2013215 (2019).","journal-title":"Nat. Mach. Intell."},{"key":"2143_CR18","unstructured":"U. S. Food and Drug Administration. Good Machine Learning Practice for Medical Device Development: Guiding Principles | FDA. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/good-machine-learning-practice-medical-device-development-guiding-principles."},{"key":"2143_CR19","first-page":"1157","volume":"3","author":"I Guyon","year":"2003","unstructured":"Guyon, I. & De, A. M. An introduction to variable and feature selection Andr\u00e9 Elisseeff. J. Mach. Learn. Res. 3, 1157\u20131182 (2003).","journal-title":"J. Mach. Learn. Res."},{"key":"2143_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/bimj.201700067","volume":"60","author":"G Heinze","year":"2018","unstructured":"Heinze, G., Wallisch, C. & Dunkler, D. Variable selection \u2013 A review and recommendations for the practicing statistician. Biom. J. 60, 431 (2018).","journal-title":"Biom. J."},{"key":"2143_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02956-2","volume":"14","author":"ED Ballard","year":"2024","unstructured":"Ballard, E. D. et al. Functional changes in sleep-related arousal after ketamine administration in individuals with treatment-resistant depression. Transl. Psychiatry 14, 238 (2024).","journal-title":"Transl. Psychiatry"},{"key":"2143_CR22","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","volume":"27","author":"RB Price","year":"2022","unstructured":"Price, R. B. et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol. Psychiatry 27, 5096\u20135112 (2022).","journal-title":"Mol. Psychiatry"},{"key":"2143_CR23","doi-asserted-by":"publisher","unstructured":"Hastie, T., Tibshirani, R. & Friedman, J. The elements of statistical learning. https:\/\/doi.org\/10.1007\/978-0-387-84858-7 (2009).","DOI":"10.1007\/978-0-387-84858-7"},{"key":"2143_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/A:1024465317902","volume":"11","author":"JD Bremner","year":"1998","unstructured":"Bremner, J. D. et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J. Trauma Stress 11, 125\u2013136 (1998).","journal-title":"J. Trauma Stress"},{"key":"2143_CR25","doi-asserted-by":"publisher","unstructured":"Wideman, T. H. et al. Beck depression inventory (BDI). Encyclopedia of Behavioral Medicine 178\u2013179 https:\/\/doi.org\/10.1007\/978-1-4419-1005-9_441 (2013).","DOI":"10.1007\/978-1-4419-1005-9_441"},{"key":"2143_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","volume":"66","author":"CG Abdallah","year":"2014","unstructured":"Abdallah, C. G., Sanacora, G., Duman, R. S. & Krystal, J. H. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med. 66, 509 (2014).","journal-title":"Annu. Rev. Med."},{"key":"2143_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41380-019-0615-x","volume":"25","author":"RB Price","year":"2020","unstructured":"Price, R. B. & Duman, R. Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model. Mol. Psychiatry 25, 530\u2013543 (2020).","journal-title":"Mol. Psychiatry"},{"key":"2143_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough, J. W., Abdallah, C. G. & Mathew, S. J. Targeting glutamate signalling in depression: progress and prospects. Nat. Rev. Drug Discov. 16, 472\u2013486 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2143_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41380-019-0400-x","volume":"24","author":"RS Duman","year":"2019","unstructured":"Duman, R. S., Shinohara, R., Foga\u00e7a, M. V. & Hare, B. Neurobiology of rapid acting antidepressants: convergent effects on GluA1-synaptic function. Mol. Psychiatry 24, 1816 (2019).","journal-title":"Mol. Psychiatry"},{"key":"2143_CR30","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20230023","volume":"96","author":"JW Gichoya","year":"2023","unstructured":"Gichoya, J. W. et al. AI pitfalls and what not to do: mitigating bias in AI. Br. J. Radio. 96, 20230023 (2023).","journal-title":"Br. J. Radio."},{"key":"2143_CR31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2215-0366(23)00183-9","volume":"10","author":"GC Medeiros","year":"2023","unstructured":"Medeiros, G. C. et al. Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies. Lancet Psychiatry 10, 790\u2013800 (2023).","journal-title":"Lancet Psychiatry"},{"key":"2143_CR32","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1503\/jpn.190156","volume":"45","author":"DA Espinoza Oyarce","year":"2020","unstructured":"Espinoza Oyarce, D. A., Shaw, M. E., Alateeq, K. & Cherbuin, N. Volumetric brain differences in clinical depression in association with anxiety: a systematic review with meta-analysis. J. Psychiatry Neurosci. 45, 406 (2020).","journal-title":"J. Psychiatry Neurosci."},{"key":"2143_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jclinepi.2016.03.002","volume":"78","author":"T van der Ploeg","year":"2016","unstructured":"van der Ploeg, T., Nieboer, D. & Steyerberg, E. W. Modern modeling techniques had limited external validity in predicting mortality from traumatic brain injury. J. Clin. Epidemiol. 78, 83\u201389 (2016).","journal-title":"J. Clin. Epidemiol."},{"key":"2143_CR34","doi-asserted-by":"publisher","first-page":"18970","DOI":"10.1073\/pnas.0804451105","volume":"105","author":"S Ganguli","year":"2008","unstructured":"Ganguli, S., Huh, D. & Sompolinsky, H. Memory traces in dynamical systems. Proc. Natl. Acad. Sci. USA 105, 18970\u201318975 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2143_CR35","first-page":"243","volume":"399","author":"MF Barnsley","year":"1985","unstructured":"Barnsley, M. F. & Demko, S. Iterated function systems and the global construction of fractals. Proc. R. Soc. Lond. A Math. Phys. Sci. 399, 243\u2013275 (1985).","journal-title":"Proc. R. Soc. Lond. A Math. Phys. Sci."},{"key":"2143_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fncom.2023.1199736","volume":"17","author":"J Geraci","year":"2023","unstructured":"Geraci, J. et al. Machine learning hypothesis-generation for patient stratification and target discovery in rare disease: our experience with Open Science in ALS. Front. Comput. Neurosci. 17, 1199736 (2023).","journal-title":"Front. Comput. Neurosci."},{"key":"2143_CR37","doi-asserted-by":"publisher","unstructured":"Holland, J. H. Adaptation in natural and artificial systems: an introductory analysis with applications to biology, control, and artificial intelligence. Adapt. Nat. Artif. Syst. https:\/\/doi.org\/10.7551\/MITPRESS\/1090.001.0001 (1992).","DOI":"10.7551\/MITPRESS\/1090.001.0001"},{"key":"2143_CR38","doi-asserted-by":"publisher","first-page":"110545","DOI":"10.1016\/j.isci.2024.110545","volume":"27","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Quantifying brain-functional dynamics using deep dynamical systems: technical considerations. iScience 27, 110545 (2024).","journal-title":"iScience"},{"key":"2143_CR39","unstructured":"Keymate.AI stay organized while working with ChatGPT. https:\/\/www.keymate.ai\/."},{"key":"2143_CR40","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","volume":"24","author":"AC Nugent","year":"2019","unstructured":"Nugent, A. C. et al. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol. Psychiatry 24, 1040\u20131052 (2019).","journal-title":"Mol. Psychiatry"},{"key":"2143_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-7-91","volume":"7","author":"S Varma","year":"2006","unstructured":"Varma, S. & Simon, R. Bias in error estimation when using cross-validation for model selection. BMC Bioinform. 7, 1\u20138 (2006).","journal-title":"BMC Bioinform."},{"key":"2143_CR42","first-page":"2825","volume":"12","author":"Pedregosa FABIANPEDREGOSA, F.","year":"2011","unstructured":"Pedregosa FABIANPEDREGOSA, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011).","journal-title":"J. Mach. Learn. Res."},{"key":"2143_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.drudis.2017.01.005","volume":"22","author":"A Giuliani","year":"2017","unstructured":"Giuliani, A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov. Today 22, 1069\u20131076 (2017).","journal-title":"Drug Discov. Today"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02143-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:28:55Z","timestamp":1765189735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-025-02143-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2143"],"URL":"https:\/\/doi.org\/10.1038\/s41746-025-02143-7","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.G., B.Q., M.T., C.C., and P.L. are employed by NetraMark Corp. J.G. declares that he owns substantial shares in NetraMark Holdings, which funded a major portion of this study. L.P. and L.A. are also shareholders in this company. C.A.Z.J is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorder. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. E.D.B. and C.A.Z.J. are employees of the United States Government, and this work was completed as part of their official duties as Government employees. The views expressed do not necessarily reflect the views of the NIH, the Department of Health and Human Services, or the United States Government. Funding for this work was provided in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIAMH002927). L.P. disclosures (Last 2 years): AbbVie, USA; Acumen, USA; Aicure, USA; Alexion, Italy; BCG, Switzerland; Astra-Zeneca, Italy; Boehringer Ingelheim International GmbH, Germany; EDRA-LSWR Publishing Company, Italy; GH-Pharma, Ireland; GLG-Institute, USA; Immunogen, USA; Johnson & Johnson USA; LB-Pharmaceuticals, USA; Magdalena BioSciences, USA; MSD, Italy; Sanofi-Aventis-Genzyme, France and USA; Lundbeck, Denmark and Italy; NapoPharma, USA and EU; NetraMark, Canada; Pfizer Global, USA; Relmada Therapeutics, USA; Takeda, USA. Shares\/Options: Relmada, NetraMark.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"749"}}